停用抗炎预防治疗后痛风发作:快速文献综述与Meta分析
本快速文献综述与Meta分析纳入6项临床试验及VA STOP Gout试验的汇总未发表数据(2972例参与者),评估启动或强化降尿酸治疗并联用抗炎预防治疗期间及停用后痛风发作的比例。汇总随机效应估计显示,预防治疗期间14.7%的参与者发生一次或以上痛风发作,停用后三个月为29.7%,末次研究期为12.2%;停用预防治疗前后发作比例平均差异为-14.8%(95%CI -21.2%至-8.5%,P<0.0001)。作者结论认为停用抗炎预防治疗后痛风发作常见,但可回落至预防治疗期间水平,应告知患者风险并制定发作管理计划。
要点
- 预防治疗期间14.7%的参与者发生一次或以上痛风发作。
- 停用预防治疗后三个月29.7%的参与者发生一次或以上痛风发作。
- 末次研究期12.2%的参与者发生一次或以上痛风发作。
核心结论
- 停用抗炎预防治疗后痛风发作常见,但可回落至预防治疗期间所见水平。
- 作者建议告知患者停用抗炎预防治疗后三个月内痛风发作的风险,并制定有效的痛风发作管理计划。
研究设计与样本
- 快速文献综述与Meta分析,检索PubMed从建库至2024年2月。
- 纳入标准为任何临床试验,受试者为痛风患者,至少一个研究组在开始或强化降尿酸治疗同时联用抗炎预防治疗,并报告预防治疗期间及之后发生一次或以上痛风发作的参与者百分比。
- 共纳入6项试验,连同VA STOP Gout试验的汇总未发表数据(2972例参与者)。
- 采用随机效应Meta分析生成各时期发生一次或以上痛风发作参与者百分比的汇总估计。
主要发现
- 预防治疗期间发生一次或以上痛风发作的汇总随机效应估计为14.7%(95%CI 11.3-18.5%)。
- 停用预防治疗后三个月内发生一次或以上痛风发作的汇总估计为29.7%(95%CI 22.9-37.0%)。
- 末次研究期发生一次或以上痛风发作的汇总估计为12.2%(95%CI 6.8-19.0%)。
- 预防治疗期间与刚停用预防治疗后发生一次或以上痛风发作参与者百分比的平均差异为-14.8%(95%CI -21.2%至-8.5%;P<0.0001)。
- 刚停用预防治疗后与末次研究期相比的平均差异为16.0%(P<0.001)。
临床怎么用
- 作者建议告知患者停用抗炎预防治疗后痛风发作的风险,并制定有效的痛风发作管理计划,尤其关注停药后三个月内。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this research was to determine how common gout flares are after ceasing anti-inflammatory prophylaxis. METHODS: A rapid literature review and meta-analysis were undertaken. PubMed was searched from inception to February 2024. Eligibility criteria included any clinical trial of people with gout with at least one arm starting or intensifying urate-lowering therapy (ULT) with coprescription of anti-inflammatory prophylaxis and that had the percentage of participants experiencing one or more gout flares reported during and after the period of prophylaxis. Random effects meta-analyses were used to generate pooled estimates of the percentage of participants experiencing one or more flares in each period. RESULTS: Six trials were included, together with aggregated, unpublished data from the VA STOP Gout trial (2,972 participants). Pooled random effects estimates of the percentage of participants having one or more gout flares were 14.7% (95% confidence interval [CI] 11.3-18.5%) during prophylaxis, 29.7% (95% CI 22.9-37.0%) in the three-month period after ceasing prophylaxis, and 12.2% (95% CI 6.8-19.0%) during the last study period. The mean difference in the percentage of participants having one or more gout flare while taking prophylaxis and immediately after ceasing prophylaxis was -14.8.0% (95% CI -21.2% to -8.5%; P < 0.0001). The mean difference from the period immediately following prophylaxis discontinuation compared to the last study period was 16.0% (P < 0.001). Sensitivity analyses indicated no material effects of prophylaxis duration, trial duration, ULT class, or placebo arms. CONCLUSION: Gout flares are common after stopping anti-inflammatory prophylaxis but return to levels seen during prophylaxis. Patients should be cautioned about the risk of gout flares and have a plan for effective gout flare management in the three months after stopping anti-inflammatory prophylaxis.
引用
- Stamp LK, Frampton C, Newcomb JA, et al. Gout Flares After Stopping Anti-Inflammatory Prophylaxis: A Rapid Literature Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2025. PMID: 39711080. doi:10.1002/acr.25486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。